Aigen Sciences key facts
- Operator of an artificial intelligence (AI) based new drug development platform intended to discover high-potency drugs.
- It has raised $12.0M; the latest was Early Stage VC in Jul 2025.
- Notable investors include Partners Investment, Premier Partners, Bluepoint Partners, K2 Investment Partners, Hyosung Ventures — 11 tracked in total.
- Status: Privately Held (backing).
Who backs Aigen Sciences
11+- ·The complete investor list: 11 names
- ·Watch Aigen Sciences: the Monday email on marks, rounds and moves
Aigen Sciences funding rounds
No funding rounds for Aigen Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Aigen Sciences investors
11 investors are on record for Aigen Sciences, including Partners Investment, Premier Partners, Bluepoint Partners and K2 Investment Partners. By type, the record holds 4 venture capital firms, 1 hedge fund and 1 private equity firm.
About Aigen Sciences
Operator of an artificial intelligence (AI) based new drug development platform intended to discover high-potency drugs. The company's platform accelerates the development of therapies by combining scientific expertise with autonomous AI systems, enabling pharmaceutical researchers to get effective drugs and achieve higher success rates in clinical trials while reducing costs and improving efficiency.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 9
- Website
- aigensciences.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Aigen Sciences doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.